Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals

This publication has 30 references indexed in Scilit:

• The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma
  Cancer Immunology, Immunotherapy, 2009
• Endogenous Naive CD8+ T Cell Precursor Frequency Regulates Primary and Memory Responses to Infection
  Immunity, 2008
• Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer
  Journal of Translational Medicine, 2008
• T cell receptor cross-recognition of an HIV-1 CD8+ T cell epitope presented by closely related alleles from the HLA-A3 superfamily
  International Immunology, 2006
• Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trial
  The Prostate, 2006
• Regulators of apoptosis: suitable targets for immune therapy of cancer
  Nature Reviews Drug Discovery, 2005
• Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin
  Vaccine, 2005
• HLA‐B35‐restricted immune responses against survivin in cancer patients
  International Journal of Cancer, 2003
• Relative dominance of HLA-B*07 restricted CD8+ T-Lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles
  Human Immunology, 2003
• Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
  Cell, 1993